Mimesis develops in silico simulation solutions for the pharmaceutical and nutraceutical sectors, specifically through its Universal Immune System Simulator (UISS), which accurately replicates human immune responses. This technology reduces the time and costs associated with drug development while minimizing the need for human participation in clinical studies.
Funding
$1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug development processes are time-consuming and expensive, often requiring extensive human participation in clinical studies, which raises ethical concerns and limits the ability to efficiently explore various biological scenarios. Accurately predicting human immune responses to new drugs and therapies remains a significant challenge.
Solution
Mimesis offers in silico simulation solutions for the pharmaceutical and nutraceutical industries, leveraging its Universal Immune System Simulator (UISS) to replicate human immune responses with high accuracy. This technology enables researchers to model and predict the effects of drugs and therapies on the immune system, reducing the need for extensive clinical trials and accelerating the drug development pipeline. The UISS platform facilitates a deeper understanding of biological scenarios, allowing for more efficient and cost-effective development of new treatments. By minimizing human involvement, Mimesis also promotes ethical standards in medical research.
Target Audience
The primary customers are biomedical companies and pharmaceutical companies seeking to reduce the time and cost of drug development while adhering to ethical standards.
Features
- Universal Immune System Simulator (UISS) accurately replicates human immune responses in a virtual environment.
- In silico trials reduce the time and costs associated with traditional drug development.
- Ready-to-use solutions for simulating various conditions, including mammary carcinoma, thyroid carcinoma, melanoma, multiple sclerosis, COVID-19, and influenza.
- UISS-Sense platform simulates human immune responses to skin sensitizers for allergenicity prediction.
- UISS-TOX platform predicts adverse outcomes such as weakened vaccine responses and increased susceptibility to infections or cancer.